UTHR United Therapeutics (UTHR) Q1 FY26 earnings call
United Therapeutics reported a strong quarter driven by significant advancements in its pipeline, particularly with ralinepag for PAH and Tyvaso for IPF, which are poised to become best-in-class therapies. The company is aggressively pursuing multiple formulations and indications, including a newly unveiled ralinepag DPI, to expand market reach and expects substantial revenue growth in the coming years. Despite some Q1 headwinds from seasonality and weather, underlying demand metrics for existing products show positive trends, positioning the company for sustained double-digit long-term growth
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.